Safely accelerating drug development for brighter outcomes

Importance of the topic

Reliable analytical and materials-characterization tools are essential across the pharmaceutical lifecycle to ensure product safety, efficacy, and regulatory compliance. Integrated spectroscopy, extrusion and rheology platforms, coupled with validated software and comprehensive service, accelerate development timelines, enable robust quality control and support the transition from laboratory feasibility to continuous industrial manufacturing.

Objectives and overview

This document presents Thermo Fisher Scientific’s integrated portfolio of spectroscopy instruments, extrusion equipment, materials-characterization tools and software tailored for pharmaceutical R&D, development, clinical studies and manufacturing. The primary objective is to show how a coordinated instrument and software ecosystem supports quality assurance, data integrity (including 21 CFR Part 11 compliance), process analytics and scalable manufacture (including hot-melt extrusion and twin-screw granulation).

Methodology and approach

The offering is framed around a drug-development workflow spanning four stages: research & discovery, development (pilot scale), clinical studies and manufacturing. Across each stage, specific analytical techniques and process tools are recommended to address material identification, polymorph and amorphous content assessment, inline Process Analytical Technology (PAT), rheological characterization, and formulation scale-up via extrusion technologies.

Instrumentation used

• Vibrational spectroscopy: FTIR (Nicolet Summit), Raman (DXR series), NIR for PAT.
• UV-Vis and micro UV (Evolution 350, NanoDrop One) for concentration, purity and microvolume assays.
• X-ray diffraction (ARL EQUINOX XRD, SolstiX software) for polymorph identification and amorphous/crystalline quantification.
• Elemental and surface methods: XPS, EDS for composition and contamination analysis.
• Rheometers and viscometers for measuring flow and viscoelastic properties relevant to compounding and extrusion.
• Extruders: Pharma mini HME (micro-compounder), Pharma 11, Pharma 16 and Pharma 24 twin-screw extruders supporting HME and twin-screw granulation (TSG) with scalable throughput options.
• Software: OMNIC Paradigm and Security Suite, ValPro packages, SolstiX XRD software with Security Suite—providing audit trails, validated configurations and 21 CFR Part 11 compatibility.

Main results and discussion

The portfolio enables end-to-end analytical support for pharmaceutical workflows by combining non-destructive, fast spectroscopic assays with process-scale extrusion platforms. Key strengths include:

• Scalability: the extruder family allows progression from gram-scale feasibility (Pharma mini HME) through pilot (Pharma 11/16) to commercial production (Pharma 24), preserving formulation characteristics and enabling straightforward PAT integration.
• Data integrity and regulatory readiness: software packages support validated configurations, centralized spectral databases, audit trails and features required for 21 CFR Part 11, USP and EP compliance.
• Process control and PAT: NIR and inline Raman enable real-time monitoring of extrusion and granulation, reducing offline sampling and improving batch consistency.
• Quality assurance: XRD and Raman provide polymorph and amorphous-phase assessment critical for stability and bioavailability; FTIR and UV-Vis support raw material ID and finished-product QC.
• Service ecosystem: global application support, on-site qualification (IQ/OQ/PQ), calibration, digital remote support and tailored service contracts minimize downtime and accelerate regulatory readiness.

Benefits and practical applications

• Formulation optimization: Hot-melt extrusion improves solubility, taste-masking and consistent API dispersion and shortens time from feasibility to production.
• Continuous manufacturing enablement: Twin-screw granulation facilitates continuous production, reducing batch variability and increasing throughput.
• Efficient QA/QC workflows: Fast, non-destructive spectroscopic methods reduce sample handling and enable high-throughput screening in discovery and QC labs.
• Regulatory compliance: Validated software and secure data management reduce the burden of audit preparation and regulatory filings.
• Reduced development risk: Combined analytical and process tools identify polymorphism, contamination and stability issues early, lowering late-stage failure risk.

Future trends and potential applications

• Expanded PAT adoption: Wider deployment of inline NIR and Raman with closed-loop control will support real-time release testing and adaptive process control.
• Digital integration: Stronger links between instrument software, LIMS and enterprise systems will enable automated data flows, advanced analytics and AI-driven process optimization.
• Continuous and hybrid manufacturing: Growth in TSG/HME hybrid modes and modular downstream equipment will promote more flexible production footprints for personalized and small-batch medicines.
• Regulatory evolution and validation automation: Increasing regulatory expectations for data integrity will drive further standardization and vendor-supplied validated workflows and qualification toolkits.
• Advanced material characterization: Higher-resolution spectroscopic imaging and correlative analytics (e.g., Raman + XRD + microscopy) will deepen understanding of microstructural determinants of bioavailability and stability.

Conclusion

Thermo Fisher Scientific’s combined instrumentation, validated software and global service capabilities present a coherent solution for pharmaceutical laboratories seeking to accelerate development while maintaining regulatory compliance. The integrated approach—from spectroscopic profiling and rheological assessment to scalable extrusion technologies and PAT—supports robust formulation development, reliable process scale-up and continuous manufacturing, all backed by data-integrity frameworks and worldwide support.

References

1. Thermo Fisher Scientific: Portfolio overview—spectroscopy, extrusion and materials characterization for pharmaceutical development (company technical brochure, 2021).
2. Case study: FT-NIR for pharmaceutical melt extrusion process monitoring (Thermo Fisher Scientific application note).
3. Case study: Confocal Raman analysis of a transdermal nicotine patch using Raman microscopy (application note).
4. Technical note: Dynamic structural studies of pharmaceutical products using ARL EQUINOX X-ray diffractometers.
5. Application note: Evaluating active ingredients in hot melt extrusion products with Raman imaging.